Comparative assessment of multiple COVID-19 serological technologies supports continued evaluation of point-of-care lateral flow assays in hospital and community healthcare settings
Open accessPublished version of a preprint
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
There is a clear requirement for an accurate SARS-CoV-2 antibody test, both as a complement to existing diagnostic capabilities and for determining community seroprevalence. We therefore evaluated the performance of a variety of antibody testing technologies and their potential use as diagnostic tools. Highly specific in-house ELISAs were developed for the detection of anti-spike (S), -receptor binding domain (RBD) and -nucleocapsid (N) antibodies and used for the cross-comparison of ten commercial serological assays-a chemiluminescence-based platform, two ELISAs and seven colloidal gold lateral flow immunoassays (LFIAs)-on an identical panel of 110 SARS-CoV-2-positive samples and 50 pre-pandemic negatives. There was a wide variation in the performance of the different platforms, with specificity ranging from 82% to 100%, and overall sensitivity from 60.9% to 87.3%. However, the head-to-head comparison of multiple sero-diagnostic assays on identical sample sets revealed that performance is highly dependent on the time of sampling, with sensitivities of over 95% seen in several tests when assessing samples from more than 20 days post onset of symptoms. Furthermore, these analyses identified clear outlying samples that were negative in all tests, but were later shown to be from individuals with mildest disease presentation. Rigorous comparison of antibody testing platforms will inform the deployment of point-of-care technologies in healthcare settings and their use in the monitoring of SARS-CoV-2 infections.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antibody responses to SARS-CoV-2 in patients with COVID-19
Long, Q.-X., Liu, B.-Z., Deng, H.-J., Wu, G.-C., Deng, K., Chen, Y.-K., Liao, P., Qiu, J.-F., Lin, Y., Cai, X.-F., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0897-1 · Cited by 2,876
Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019
Zhao, J., Yuan, Q., Wang, H., Liu, W., Liao, X., Su, Y., Wang, X., Yuan, J., Li, T., Li, J., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa344 · Cited by 2,607
A serological assay to detect SARS-CoV-2 seroconversion in humans
Amanat, F., Stadlbauer, D., Strohmeier, S., Nguyen, T. H. O., Chromikova, V., McMahon, M., Jiang, K., Arunkumar, G. A., Jurczyszak, D., Polanco, J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0913-5 · Cited by 1,769 · cited 1×
“The RBD plasmid was obtained from Florian Krammer at Mount Sinai University [18].”
MethodPotent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability
Brouwer, P. J. M., Caniels, T. G., van der Straten, K., Snitselaar, J. L., Aldon, Y., Bangaru, S., Torres, J. L., Okba, N. M. A., Claireaux, M., Kerster, G., et al. (2020) · Science · doi:10.1126/science.abc5902 · Cited by 1,140 · cited 1×
“S protein consists of a pre-fusion S ectodomain residues 1–1138 with proline substitutions at amino acid positions 986 and 987, a GGGG substitution at the furin cleavage site (amino acids 682–685) and an N terminal T4 trimerisation domain followed by a Strep-tag II [17].”
BackgroundSelf-citation(2020) · doi:10.1101/2020.04.15.20066407 · Cited by 278
Research works printed but not linked: 9
- KK To, 2020, Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study, Lancet Infect Dis, 20, 565, 10.1016/S1473-3099(20)30196-1 · DOI · Paper page
- L Zou, 2020, SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients, N Engl J Med, 382, 1177, 10.1056/NEJMc2001737 · DOI · Paper page
- L Verdoni, 2020, An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study, Lancet
- E Whittaker, 2020, Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2, JAMA
- HE Randolph, 2020, Herd Immunity: Understanding COVID-19, Immunity, 52, 737, 10.1016/j.immuni.2020.04.012 · DOI · Paper page
- Whitman JD, Hiatt J, Mowery CT, Shy BR, Yu R, Yamamoto TN, et al. Test performance evaluation of SARS-CoV-2 serological assays. medRxiv 2020.04.25.20074856 [Preprint]. 2020 [cited 2020 May 29]. https://doi.org/10.1101/2020.04.25.20074856. · DOI
- Lassaunière R, Frische A, Harboe ZB, Nielsen ACY, Fomsgaard A, Krogfelt, Jørgensen CS. Evaluation of nine commercial SARS-CoV-2 immunoassays. medRxiv 2020.04.09.20056325 [Preprint]. 2020 [cited 2020 May 29]. https://doi.org/10.1101/2020.04.09.20056325. · DOI · Paper page
- Tan W, Lu Y, Wang J, Dan Y, Tan Z, He, X, et al. Viral Kinetics and Antibody Responses in Patients with COVID-19. medRxiv 2020.03.24.20042382 [Preprint]. 2020 [cited 2020 May 29]. https://doi.org/10.1101/2020.03.24.20042382. · DOI · Paper page
- O Sobolev, 2016, Adjuvented influenza-H1N1 vaccination reveals lymphoid signatures of age-dependent early responses and of clinical adverse events, Nat Immunol, 17, 204, 10.1038/ni.3328 · DOI · Paper page
Cited by
Seow, J., Graham, C., Merrick, B., Acors, S., Pickering, S., Steel, K. J. A., Hemmings, O., O’Byrne, A., Kouphou, N., Galao, R. P., et al. (2020) · Nature Microbiology · doi:10.1038/s41564-020-00813-8 · Cited by 1,419
Self-citationA dynamic COVID-19 immune signature includes associations with poor prognosis
Laing, A. G., Lorenc, A., del Molino del Barrio, I., Das, A., Fish, M., Monin, L., Muñoz-Ruiz, M., McKenzie, D. R., Hayday, T. S., Francos-Quijorna, I., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1038-6 · Cited by 946
Self-citationMonin, L., Laing, A. G., Muñoz-Ruiz, M., McKenzie, D. R., del Molino del Barrio, I., Alaguthurai, T., Domingo-Vila, C., Hayday, T. S., Graham, C., Seow, J., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00213-8 · Cited by 611
Self-citationLong COVID burden and risk factors in 10 UK longitudinal studies and electronic health records
Thompson, E. J., Williams, D. M., Walker, A. J., Mitchell, R. E., Niedzwiedz, C. L., Yang, T. C., Huggins, C. F., Kwong, A. S. F., Silverwood, R. J., Di Gessa, G., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30836-0 · Cited by 600
Self-citationCarter, M. J., Fish, M., Jennings, A., Doores, K. J., Wellman, P., Seow, J., Acors, S., Graham, C., Timms, E., Kenny, J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1054-6 · Cited by 419
Self-citation
Metadata
- Authors
- Pickering, S., Betancor, G., Galão, R. P., Merrick, B., Signell, A. W., Wilson, H. D., Kia Ik, M. T., Seow, J., Graham, C., Acors, S., Kouphou, N., Steel, K. J. A., Hemmings, O., Patel, A., Nebbia, G., Douthwaite, S., O’Connell, L., Luptak, J., McCoy, L. E., Brouwer, P., van Gils, M. J., Sanders, R. W., Martinez Nunez, R., Bisnauthsing, K., O’Hara, G., MacMahon, E., Batra, R., Malim, M. H., Neil, S. J. D., Doores, K. J., & Edgeworth, J. D.
- Venue
- PLOS Pathogens
- Publisher
- Public Library of Science (PLoS)
- Published
- 2020-09-24
- Volume
- 16
- Issue
- 9
- Pages
- e1008817
- ISSN
- 1553-7366 (ISSN-L)
- 1553-7374
- OpenAlex
- W3088689466
- Cited by
- 107
- References
- 5
- FWCI
- 3.02
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.